Frontier Bio vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 34)
Frontier Bio logo

Frontier Bio

EmergingLife Sciences & BioTech

Bioprinting & Tissue Engineering

Frontier Bio develops living vascular grafts and bioprinted human tissue for pharmaceutical testing and future organ donation, using a 4D self-assembly approach to create complex lung, brain, and vascular microtissues without animal testing.

AI VisibilityBeta
Overall Score
D34
Category Rank
#187 of 198
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
31
Gemini
28

About

Frontier Bio is a biotechnology company focused on tissue engineering and regenerative medicine, developing engineered human tissues as alternatives to animal models in pharmaceutical testing and as the foundational building blocks for future transplantable organs. The company combines advanced bioprinting techniques with stem cell self-assembly — a process it describes as "4D printing" — in which cells are guided to autonomously organize into complex tissue structures, such as the branching alveolar architecture of human lung tissue.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

34
Overall Score
74
#187
Category Rank
#11
75
AI Consensus
68
stable
Trend
stable
39
ChatGPT
71
31
Perplexity
68
28
Gemini
80
31
Claude
77
33
Grok
69

Key Details

Category
Bioprinting & Tissue Engineering
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.